title: In vitro cytotoxic effects of stabilizing sugars within human intravenous immunoglobulin preparations against the human macrophage THP-1 cell-line.
abstract: Intravenous immunoglobulin (IVIg) is a safe and effective therapy for the treatment of primary and secondary humoral immune deficiencies and autoimmune disorders. Both minor and more serious side effects may occur following IVIg administration in approximately 1-15% of infusions and stabilizing sugars found in IVIg preparations may contribute some of these. In this report, we aimed to determine the cytotoxic effects of IVIg as compared with four stabilizing sugars (glucose, sucrose, maltose and D-sorbitol) found in IVIg preparations on human monocyte-macrophages. The human THP-1 macrophage cell-line was used as a model to determine the effects of stabilizing sugars and IVIg preparations on cell viability and growth. The sugars differentially affected the viability of THP-1 cells. In experiments using doses of the sugars commonly found in IVIg preparations, cell viability and proliferation was unaffected when compared with doses of IVIg typically administered to patients (5 mg/ml). However, in an LDH-release cell lysis assay that measures changes in cell permeability, glucose (50 mg/ml) induced significant release of LDH as compared with complete IVIg (5 mg/ml, p<0.0001). Intranucleosomal DNA fragmentation was not detected at therapeutically relevant doses of IVIg. This suggested that THP-1 cell death was not due to apoptosis. We conclude that osmotic stress mediated by the sugars at high doses promoted THP-1 cell death. We propose that IVIg per se is not cytotoxic to the autonomously growing human THP-1 cell-line but rather, the stabilizing sugars used in the preparations are the cytotoxic factors. This observation was evident when preparations of IVIg were used at high concentrations but not at levels one would associate with clinically relevant doses of IVIg.
authors.affiliation: Department of Neurology, The Neuromuscular Research Laboratory, The Johns Hopkins University School of Medicine, Baltimore, MD 21287-7881, USA. mawilliams888@aol.com
authors.forename: Marc A
authors.initials: MA
authors.lastname: Williams
authors.forename: Chris J
authors.initials: CJ
authors.lastname: Rhoades
authors.forename: Drew
authors.initials: D
authors.lastname: Provan
authors.forename: Adrian C
authors.initials: AC
authors.lastname: Newland
mesh_terms: D002241:Carbohydrates / Q000009:adverse effects*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002463:Cell Membrane Permeability / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D053938:DNA Fragmentation / Q000187:drug effects; D005079:Excipients / Q000009:adverse effects*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008264:Macrophages / Q000166:cytology / Q000187:drug effects*; D009997:Osmotic Pressure / Q000187:drug effects
chemical_list: D002241:Carbohydrates; D005079:Excipients; D016756:Immunoglobulins, Intravenous; D007770:L-Lactate Dehydrogenase